PCT LTD announced that in conjunction with PCT (Europe) Ltd., their efforts to commercialize its Annihilyzer Infection Control Systems with the United Kingdom’s National Health Service has taken a significant step forward, according to a senior executive of NTH Solutions UK, a subsidiary of North Tees NHS Foundation Trust, who are also PCT Europe’s exclusive trading partner. The Hospital will commence the final evaluation of PCTL’s Annihilyzer® on the live Wards following initial results that provided the evidence needed to allow the Hospital’s Infection Control Director to authorize the final phase of testing. This live study will be fully supported by the Infection Control and Operational Decontamination Cleaning Teams. The final stage of the study will utilize the National Institute of Health Research protocols, which will be clinically sponsored by Teesside University’s Microbiology Department. The 8 fully patient occupied Wards being used for the study have been subject to COVID-19 outbreaks and regular Hospital Associated Infections. The University will assist in the collection of base line and pre-evaluation information collected during and post-evaluation to ensure a broad representation of data, which will be published in support of the system and the HOCl fluids it generates.